Key factors
sym | IMRN |
exch | US |
MCap | 21.75M |
Beta | 1.058 |
EPS | -0.45 |
Div date | 0000-00-00 |
Yesterday
sym | IMRN |
exch | US |
close | 2.31 |
50 Day MA | 1.883 |
200 Day MA | 1.913 |
52 Week High | 5.96 |
52 Week Low | 1.481 |
Target Price | 6.41 |
Market Cap Mln | 21.75 |
Share statistics
Shares Outstanding | 5694.96K |
Shares Float | 188.36M |
Percent Institutions | 0.125 |
SharesShort | 1208.0 |
Short Ratio | 0.31 |
Shares Short Prior Month | 7233.0 |
Short Percent | 1.600 |
Income
Revenue TTM | 3576.64K |
Revenue Per Share TTM | 0.64 |
Quarterly Revenue Growth YOY | 303.60 |
Gross Profit TTM | 1740.08K |
EBITDA | -3386.3K |
Diluted Eps TTM | -0.45 |
earning
Operating Margin TTM | -0.78 |
Earnings Share | -0.45 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | -1.63 |
Enterprise Value Revenue | 1.775 |
Book Value /share | 0.077 |
Price Book MRQ | 2.273 |
Price Sales TTM | 6.098 |
ProfitMargin | -1.08 |
ReturnOnAssetsTTM | -0.09 |
ReturnOnEquityTTM | -0.20 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US45254U1016 |
CIK | 1660046 |
Code | IMRN |
CUSIP | 45254U101 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-03-08 |
Home Category | ADR Primary |
info
Fiscal Year End | June |
Full Time Employees | 6.0 |
IPODate | 2017-06-09 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Immuron Ltd ADR |
Address | 62 Lygon Street, Carlton, VIC, Australia, 3053 |
Country Name | USA |
Phone | 61 3 9824 5254 |
Web URL | https://www.immuron.com.au |
Logo URL | /img/logos/US/IMRN.png |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.